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ABSTRACT 
Background  
Point-of-care detection of urine lipoarabinomannan (LAM) is a low-cost rapid TB 
diagnostic for use in HIV co-infected patients. However, its sensitivity in these 
patients is suboptimal. Strategies to improve its performance is a need. The 
hypothesis was that early morning urine (EMU), rather than random urine 
sampling, would improve LAM’s sensitivity. 
Methods 
Recruitment process conducted between June 2012 and February 2014 for HIV-
infected patients from four hospitals in Cape Town, South Africa presenting with 
possible TB (all patients initiated on TB treatment). Fresh random and early 
morning urine (EMU) samples (~10-30 ml) collected in sterile containers. 
Following the manufacturer’s instructions, an Alere Determine TB Lateral flow 
assay performed on each sample, using both grade 1 and 2 cut-points. A single 
sputum Xpert MTB/RIF and/or liquid TB culture was a reference standard. Those 
designated probable TB patients were sputum Xpert MTB/RIF and/ TB culture 
negative, but started on TB treatment.  
Results 
Of 184 HIV- infected adults screened, only 123 patients commenced anti-TB 
treatment  and provided matched random and  EMU samples. 33% (41/123) and 
67% (82/123) had definite TB and probable TB, respectively. Amongst definite TB, 
LF-LAM sensitivity, using the grade 2 cut-point, increased to 39% (95% CI: 26-54, 
16/41) from 12% (95% CI: 5-24, 5/41) using EMU versus random, respectively 
(p=0.004). Similarly, amongst probable TB, urine LAM sensitivity increased to 
24% (95% CI: 16-34, 20/82) (p=0.01) from 10% (95% CI: 5-17, 8/82). Age, CD4 cell 
count, Xpert MTB/RIF/liquid TB culture positivity and prior initiation of anti-TB 
treatment within 7 days were not significant predictors of an increasing urine 
LAM grade between random and EMU specimens.  LF-LAM specificity was not 
determined. 
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Conclusions 
EMU sampling can improve the sensitivity of LF-LAM testing for hospitalised 
TB/HIV co-infected patients. There is a need for further research is to assess if this 
additional diagnostic sensitivity can affect patient-important outcomes.  
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ABBREVIATIONS 
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CHAPTER 1: LITERATURE REVIEW  
 
Introduction  
Tuberculosis (TB) is an enormous global health problem. Annually approximately 9 
million people develop TB, and over 1.7 million deaths are attributed to TB (1). South 
Africa is one of the countries with the highest burden of TB. Worldwide, South Africa has 
a higher incidence than India and China, and this has increased by 400% over the past 15 
years (2).    
World Health Organization (WHO) statistics estimate South Africa to have an incidence of 
450,000 cases of active TB per annum (1), representing approximately 1% of its population. 
Of the 450,000 new cases WHO estimates that approximately 270,000 (60%) are co-infected 
with the human immunodeficiency virus (HIV). The latest figure from the South African 
Department of Health is that 73% of adult TB patients are HIV positive (2). When a patient 
is infected with both Mycobacterium tuberculosis (M.tb) and HIV, the two pathogens interact 
synergistically (Figure 1) speeding the progression of illness and increasing the likelihood 
of death (3). The presence of HIV makes a person more vulnerable to developing TB, and 
having TB accelerates the progression of HIV infection (3). TB is the most common 
opportunistic infection among persons presenting with HIV. Furthermore HIV–infected 
patients with TB are at a higher risk of death (3, 4). 
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Figure 1. The synergy of HIV and TB 
 
The low case-detection rate is largely due to reduced capacity amongst resource-limited 
national TB programmes. It is compounded by ineffective diagnostic algorithms that 
incorporate decade-old tests with sub-optimal diagnostic accuracy (5). A delay in TB 
diagnosis is associated with high mortality even in richly-resourced settings (6). 
1.1. Diagnosis in HIV/ TB co-infection  
In the majority of disease-endemic countries, sputum microscopy, a method introduced 
over a century ago, is still the first line diagnostic test for TB. In adult pulmonary TB without 
immune suppression it has reasonable sensitivity compared to culture (7). However, for 
detection of TB in children, TB/HIV co-infected patients and extra-pulmonary TB (EPTB) 
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its sensitivity drops to unacceptable levels (8). In  cases of TB in children, smear microscopy 
needs to be performed on paucibacillary non-sputum based biological fluids (8).  
In HIV co-infection, reduced smear microscopy sensitivity is the result of a failed 
inflammatory response with consequent reduced caseating necrosis and lower numbers of 
acid-fast bacilli in the airway (9). Another diagnostic problem in severely ill TB/HIV co-
infected patients is that they are often unable to self-expectorate sputum or have extra-
pulmonary disease. Acquiring a specimen for TB diagnosis in these patients therefore 
requires assisted sputum sampling e.g. via hypertonic saline induction or alternative 
invasive sampling (10). In many TB/HIV endemic countries, capacity for assisted and 
invasive sampling is limited or unavailable. Furthermore, laboratory capacity for culture-
based diagnosis is limited. Thus, especially in settings with dual epidemics of HIV and TB, 
the lack of accurate and rapid diagnostic TB testing is a major impediment to achieving 
global TB control. There is a great need to develop alternative rapid-diagnostic methods 
that are more sensitive and specific than smear microscopy and better able to detect TB 
disease at different sites the body (6). 
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Figure 2: Figure 2:  The global TB diagnostics pipeline in 2015 (11). 
 
 
 
The development of the Xpert MTB/RIFXpert (Cepheid, Sunnyvale,CA, USA) assay, a 
nucleic acid amplification test (NAAT) able to detect the presence of both M.tb complex 
DNA and rifampicin drug resistance (strongly correlated with MDR-TB) in less than 2 hours, 
provided a major advance in TB diagnosis (Figure 3). The WHO endorsed the use of the 
Xpert MTB/RIF assay for frontline TB diagnosis in HIV-infected and MDR-TB suspects in 
December 2010 (12). When compared to smear microscopy the Xpert MTB/RIF assay 
provides clear clinical benefits for the early diagnosis of suspected pulmonary TB cases (13).  
The Xpert MTB/RIF assay requires sputum for testing and has reduced performance in 
HIV-infected compared to uninfected patients and on extrapulmonary compared to sputum 
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samples (13). Despite international efforts to reduce costs, a single test cartridge still costs ~ 
US$9.98 and a four-cartridge machine ~US$17 000, making implementation unaffordable at 
present in a number of high burden settings. The Xpert MTB/RIF assay cannot differentiate 
between the presence of viable or dead bacilli, increasing the risk of false positive results 
amongst patients with previous TB infection, common in HIV co-infected patients with 
advanced immunosuppression (14, 15). The Xpert MTB/RIF assay is not a true point-of-
care test. Large studies using the Xpert MTB/RIF assay in primary care clinics, showed that 
the test increased the number of individuals with bacteriologically confirmed TB, and 
reduced time to treatment initiation particularly among HIV-infected participants (16). 
However, the use of the Xpert MTB/RIF assay did not affect TB-related morbidity or 
mortality (16). Nevertheless, the Xpert MTB/RIF assay is a major advance on smear 
microscopy, especially for HIV co-infected patients with advanced immunosuppression 
and possible TB, non-sputum based, inexpensive point-of-care diagnostics are still urgently 
required. 
TB culture remains the gold standard diagnostic test for TB in both immunocompetent and 
compromised patients. Amongst HIV-infected patients it is often the only method of 
confirming TB. Consequently, the WHO and affiliated organisations such as FIND 
diagnostics continue to mobilise international resources to strengthen culture capacity in 
high burden resource-limited settings. Culture is also a critical diagnostic modality in 
settings of high MDR and XDR-TB, however there is a need for culture based technology 
for extended drug sensitivity testing (17). TB culture , takes up to 6 weeks to provide results, 
and requires considerable laboratory infrastructure (18). In the context of severe TB disease, 
treatment decisions are rarely based on culture results, a finding illustrated in a number of 
studies (16).  
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Figure 3: The progress of frontline TB diagnosis from smear microscopy to molecular methods and onwards 
toward point-of-care test formats (19) 
 
 
 
For decades, researchers and the industry had pinned their hopes on serological antibody-
detection methods for a bedside TB test. Consequently, TB immunodiagnostics, such as 
serological tests, tuberculin tests (TSTs) and interferon- release assays (IGRAs), have been 
extensively studied (20). The failure to develop antibody-based TB tests that meet clinical 
needs does not imply that biomarker approaches should be abandoned. For instance, M.tb 
metabolites can be detected as volatile organic compounds (VOCs) in breath, using gas 
chromatography/mass spectrometry-based analysers (21). Recently, a breath test identified 
biomarkers of active pulmonary TB with 85% accuracy in symptomatic high-risk subjects 
(22). In addition, Banday et al demonstrated the potential utility of urine VOCs in the 
diagnosis of TB disease (23). VOC detection offers potential advantages, but they remain 
under development and a long way from clinical use.  
The use of urine, rather than sputum, for diagnostic testing provides an appealing 
alternative. Collection is easy and less invasive, it is readily available, and its collection 
presents a very low infection risk to staff. In fact, urine antigen detection is the most 
common diagnostic technique employed for a number of infectious diseases e.g. Leginella. 
Its use for TB diagnosis is a focus of research and development. Lipoarabinomannan (LAM) 
is the most extensively evaluated and promising, and is commercially available as a bedside 
test (24).  
 
  
 
A.Flourescence LED 
Microscopy 
B. Automated intergrated NAATs- 
Xpert MTB-RIF 
C. Immunochromatographic strip test e.g. Urine 
LAM strip test (Determine TB LAM Ag test, Alere) 
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1.2. Urine LAM for TB diagnosis 
1.2.1 What is Lipoarabinomannan (LAM)? 
LAM is a heat-stable 17.5kD glycolipid that forms one of the main components of the outer 
cell wall of mycobacterial species (Figure 4). It is a heterogeneous immune-reactive 
glycoconjugate (25), that accounts for up to 15% of the total bacterial weight and is an 
important virulence factor of M.tb (26).  
LAM consists of three distinct structural domains: a phosphatidylinositol (PI) anchor, a 
branched mannan and a branched arabinan (24).  
 
 
Figure 4: Simplified illustration of the M.tb cell wall, showing the position of LAM (27) 
   
1.2.2 Why is LAM detected in the urine? 
LAM can be detected in the urine of patients with active TB.  It travels in the bloodstream 
and passes through the renal filtration barrier without major changes, thus being detectable 
in an antigenically intact form in urine (Figure 5) (28) .  
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Figure 5: Annotated diagram, illustrating the passage of mycobacterial DNA and LAM antigen from its 
infection site to expulsion in the urine (25) 
 
 
LAM is detectable in highly varying concentrations in the urine of TB patients following the 
highly variable sensitivity of the LAM assay in different groups of TB patients. Most notably, 
LAM is found in the highest concentrations amongst HIV infected patients with advanced 
immunosuppression and disseminated TB. 
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Figure 6: Three proposed models showing the possible fate of LAM molecules released from 
systemic or urinary M.tb organisms (29) 
 
 
The current thinking about the mechanisms by which LAM concentration is affected in 
urine are depicted in Figure 6. These include:  
A.  Systemically-released LAM binds to an antibody forming an immune complex that is not 
able to pass across the glomerular membrane, and is therefore not present in urine. This 
model may account for the failure to detect LAM in the urine despite the presence of 
pulmonary M.tb. or a low bacillary burden. 
B.  Circulating LAM, unattached to a specific anti-LAM antibody, is freely filtered through the 
kidney into the urine, giving rise to a positive LAM test if antigen concentration saturates 
mechanism A (high bacillary load).   
C. M.tb within the renal tract releases LAM directly into the urine, which gives rise to a positive 
LAM test in the presence of M.tb organisms in the kidney (29). 
This model explains, in part, why LAM has been found in higher concentration in the urine 
of patients with advanced HIV infection and disseminated forms of TB as a high bacillary 
load would lead to a higher antigenemia (30). Additionally, increased LAM detection has 
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been noted in patients with abnormal renal function due to the presence of TB bacilli in 
renal parenchyma (29). This finding was supported by the detection of bacilli in the urine 
by Xpert MTB/RIF (31). Alterations in the podoctye barrier (filtration barrier), with a 
resultant in increase in glomerular permeability could also increase urinary LAM 
concentrations.  
1.2.3 Development of the LAM-ELISA 
In 2001, Hamasur and colleagues developed an ELISA method for the detection of LAM, 
using a polyclonal anti-LAM antibody, and found LAM to be detectable in mouse urine, 
post M.tb intraperitoneal injection (32). The methods were highly sensitive, detecting LAM 
at concentrations of 1 ng/ml and 5 pg/ml (32). In 2005, the pre-commercial prototype of the 
LAM ELISA (M. tuberculosis LAM ELISA Test®, Chemogen, and Portland, USA) was first 
tested, using human urine specimens in a Tanzanian cohort of TB patients (33). This pre-
commercial version was superseded by the development of a second generation, 
commercially-available prototype known as the Clearview® TB ELISA (Inverness Medical 
Innovations, USA) and retailed as the TB LAM ELISA (Alere, USA; henceforth called LAM-
ELISA), using the original polyclonal anti-LAM antibody. 
1.2.4 Development and use of the LAM lateral flow assay 
In 2008, Alere Medical Innovations developed a simple lateral flow format, using the same 
polyclonal anti-LAM antibody coupled to gold nanoparticles (34). The Alere DetermineTM 
TB LAM Antigen lateral flow assay (Alere, USA; henceforth called the LF-LAM test) was 
the first commercially available true point-of-care TB test, requiring only 60 l of 
unprocessed urine (Figure 7).  
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Figure 7: Alere DetermineTM TB LAM Ag test. 60 ls of urine is applied to the urine loading platform 
(left arrow). After a 25 minute incubation period, the colour intensity of the patient 
window band (middle arrow) is graded (0 – 5) using the test’s reference scale card, so 
determining a patient’s TB status (35).  
 
 
 
The test costs less than US$3 can be performed at the patient’s bedside, thus obviating the 
use of laboratory infrastructure and trained personnel. The test, shown in Figure 7, is 
performed by applying 60 ls of urine to the loading platform, incubating it at room 
temperature for 25 minutes (36), then comparing the colour intensity of the band in the 
patient window against those on the ‘reference scale card’ supplied by the manufacturer. 
Colour intensity ranges from 0 - 5. The test is only valid if a band appears in the control 
window.  
Initially, the manufacturer categorised patients with grade 0 as test ‘negative’, whereas grades 
1 to 5 were classified as test ‘positive’. However, in a test where rule-in utility needs to be 
optimised due to sub-optimal sensitivity, the grade-1 cut-point was found to lack specificity 
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and have decreased inter-observer agreement (37). Consequently, in early 2014 the 
manufacturer removed the old grade 1 colour category replacing it with  the original grade 2 
colour category, and adjusting the other categories accordingly, so reducing the range to 
five (0 - 4).  
1.2.5 LAM ELISA diagnostic accuracy 
The LAM-ELISA for TB has been extensively evaluated (Table 1). Apart from the early 
studies by Boehme et al. in 2005 (33)and Tessema et al. in 2002 (38), the overall sensitivity of 
LAM-ELISA has been modest, ranging from 13% - 51% for the diagnosis of active 
pulmonary TB (26). However, amongst HIV-infected patients with advancing 
immunosuppression (lower CD4 cell counts) and hospitalised in-patients with higher 
burdens of disease, urine LAM-ELISA sensitivities improved to potentially useful levels 
(31). In addition, incremental sensitivity over sputum smear microscopy was noted, such 
that the combination of sputum smear microscopy and LAM-ELISA was able to detect as 
many as 75% of TB in patients with CD4200 cells/mm3 (37). Thus, urine LAM-ELISA 
seemed to offer the greatest potential as an add-on TB diagnostic for HIV co-infected 
patients with advanced immunosuppression (39). This offers particular utility given that 
sputum-based conventional and novel diagnostic tools perform poorly in these vulnerable 
patients where EPTB and disseminated TB is common and TB-related mortality as high as 
50% (40). The development of the LAM-ELISA into an inexpensive lateral flow assay format 
(LF-LAM) further improved its potential utility as it enabled rapid results at a patient’s 
bedside. 
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Table 1. Performance of standardised urine LAM ELISA assays in different clinical subgroups with suspected 
TB stratified by HIV status and, where available, CD4 T cell count (25). 
 
 
 
Study 
Clinical 
subgroup 
and country 
Evaluable 
pts 
tested/ 
Total 
number 
recruited 
HIV 
(%pos.) 
Overall 
sensitivity(CI), 
HIV pos. pts 
with 
CD4< 200μl/ml 
Overall 
specificity(CI), 
HIV pos. pts 
with 
CD4< 
200μl/ml 
Overall 
PPV(CI), 
HIV pos. 
pts with 
CD4< 
200μl/ml 
Overall 
NPV(CI), 
HIV pos. 
pts with 
CD4< 
200μl/ml 
Sensitivity 
(CI) 
smear(S) 
neg. 
culture(C) 
pos. TB 
cases (n) 
(n= S-ve, 
C+ve) 
Boehme et al. 
(41) 
Outpatient 
clinic and 
healthy 
USA/local 
controls 
(Tanzania) 
 
235/333 
 
69.0% 
OVERALL          
80 
HIV+                  
81 
CD4<200          
N/R 
99 (N/R) 
N/R 
N/R 
100( N/R ) 
N/R 
N/R 
80( N/R ) 
N/R 
N/R 
(n=50)  76 
(N/R) 
N/R 
N/R 
Daley et 
al.#(42) 
Outpatient 
clinic (India) 
 
200/200 
 
8.5% 
OVERALL        
18(9-33) 
HIV+                 
20(1-77) 
CD4<200          
N/R 
88(81-92) 
83(51-97) 
N/R 
30(15-50) 
33(2-88) 
N/R 
79(72-84) 
71(42-90) 
N/R 
(n=12)   25 
(4-64)           
N/R 
N/R 
Reither et 
al.#(43) 
Outpatient 
clinic 
(Tanzania) 
 
151/291 
 
59.1% 
OVERALL      
51(38-63) 
HIV+                
62(47-75) 
CD4<200          
N/R 
88(79-94) 
84(68-94) 
N/R 
78(63-89) 
84(68-94) 
N/R 
68(58-77) 
62(47-75) 
N/R 
(n=21)    38 
(N/R) 
42 (N/R) 
N/R 
Mutetwa et 
al.#(44) 
Outpatient 
clinic 
(Zimbabwe) 
 
261/397 
 
77% 
OVERALL      
44(36-54) 
HIV+               
52(43-62) 
CD4<200          
N/R 
89(81-94) 
86(73-93) 
N/R 
84(74-91) 
84(73-92) 
N/R 
54(46-61) 
57(48-66) 
N/R 
(n=40) 28 
(13-43) 
N/R 
N/R 
Dheda et al.*1 
(25) 
Outpatient 
clinic (South 
Africa) 
 
427/500 
 
31% 
OVERALL        
13(8-19) 
HIV+                
21(11-35) 
CD4<200         
37(19-59) 
99(97-100) 
100(91-100) 
100(84-100) 
94(74-99) 
100(70-100) 
78(45-94) 
59(53-64) 
55(43-65) 
76(63-86) 
(n=70) 3 
(N/R) 
18 (N/R) 
25 (N/R) 
Lawn et al.# 
(45) 
ARV clinic, 
asymptomatic 
HIV patients 
(South Africa) 
 
235/235 
 
100% 
OVERALL     38 
(27-51) 
HIV +              38 
(27-51) 
CD4 50-100     
41(22-64) 
CD4< 50          
67(44-84) 
100 (N/R) 
100 (N/R) 
N/R 
N/R 
100(82-100) 
100(82-100) 
N/R 
N/R 
83(77-88) 
83(77-88) 
N/R 
N/R 
(n=50)  36┼ 
(N/R) 
36┼ (N/R) 
35┼ (N/R 
56┼ (N/R) 
Shah et al. 
*1(46) 
In-patients 
(South Africa) 
 
315/499 
 
85% 
OVERALL     59 
(52-66) 
HIV+               67 
(59-74) 
CD4 50-100    71 
(51-87) 
CD4 <50         85 
(73-93) 
96(91-99) 
94(87-98) 
N/R 
N/R 
73(65-80) 
75(67-82) 
N/R 
N/R 
34(29-39) 
30(25-36) 
N/R 
N/R 
(n=111)  56 
(N/R) 
N/R 
N/R 
N/R 
Gounder et al 
(47) 
Outpatient 
clinic (South 
Africa) 
 
422/443 
 
100% 
OVERALL     
32(16-52) 
 HIV+            
32(16-52) 
CD4 <200       35 
(16-57) 
CD4 <50        56 
(21-86) 
98(96-99) 
98(96-99) 
96(92-99) 
90(76-97) 
53(28-77) 
53(28-77) 
57(29-82) 
56(21-86) 
95(93-97) 
95(93-97) 
92(87-95) 
90(76-97) 
(n=19)  16 
(4-40) 
(n=19)  16 
(4-40) 
N/R 
N/R 
Talbot et al 
(48) 
In-patients 
( Dar es 
Salaam, 
Tanzania) 
 
212/278 
 
100% 
OVERALL  65 
(53-7 ) HIV+           
65 (53-76) CD4 
50-200    67 (43-
85) 
CD4 <50        77 
(58-89) 
86(79-91) 
86(79-91) 
94(79-99) 
72(56-84) 
69(56-80) 
69(56-80) 
88(60-98) 
67(49-81) 
84(76-89) 
84(76-89) 
82(66-92) 
82(65-92) 
(n=24) NR 
(n=24) NR 
N/R 
N/R 
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Hypothesis is that heat and mechanical compression of the paper matrix containing the 
urine sample - herein referred to as compressive evaporation - would cause urine to 
evaporate and LAM to accumulate, thus concentrating LAM at the heat source (Figure 8) 
(38). An additional method under investigation is heating. The drawback of all these 
methods is the requirement for laboratory infrastructure and resources, all costs that nullify 
the bedside nature of the LF-LAM test format. 
 
 
 
 
 
 
 
 
 
 
Figure 8: Schematic illustration of the compressive evaporation technology for sample 
application, evaporation and LAM concentration (49). 
 
A simple, useful strategy proposal: use the natural urine concentration method that occurs 
overnight, by collecting urine samples in the morning. Early morning urine (EMU) 
collection (after an individual awakes from sleep) is generally accepted as a more reliable 
method for detecting most antigens, since it corresponds closely with 24-h urine collection 
(50). A 24-h urine collection is considered the gold standard in studies evaluating urinary 
analytes, such as protein creatinine ratio for kidney disease. However, some studies that 
compared measurements of a EMU to a 24-h urine collection to measure albumin creatinine 
ratio (ACR), showed EMU to possess a higher sensitivity possibly due to the difficulties of 
conducting accurate 24 hour collections (51). Twenty-four hour urine collection is 
cumbersome. A practical and easier alternative is the collection of an EMU sample. It is a 
suggestion that EMU is preferred over a random urine sample (daytime random sample) 
because the former is less influenced by factors such as hydration status and physical 
activity that can reduce variability of urine analyte concentration (50, 52).  
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As with analytes, so with antigens or microorganisms. Prolonging the period between 
voiding improves total antigen excretion, so improving detection. EMU samples have also 
been a means of obtaining a microbiological diagnosis of TB. Likewise, urine-based PCR for 
M.tb has shown promise in TB/HIV co-infected patients (53). However data on the 
sensitivity of microbiological TB diagnosis using EMU is limited and available data 
suggests limited smear and culture positivity (54). 
The proposed hypothesis is that EMU sampling would increase urine LAM sensitivity 
compared to random sample collection. In addition, considering the treat-to-test hypothesis 
(55), it was considered important to explore whether initiation of empiric anti-TB treatment 
prior to EMU LAM would further improve sensitivity.  
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Background  
Point-of-care detection of urine lipoarabinomannan (LAM) is a low-cost rapid TB diagnostic for use 
in HIV co-infected patients. However, its sensitivity in these patients is suboptimal. Strategies to 
improve its performance is a need. The hypothesis was that early morning urine (EMU), rather than 
random urine sampling, would improve LAM’s sensitivity. 
Methods 
Recruitment process conducted between June 2012 and February 2014 for HIV-infected patients 
from four hospitals in Cape Town, South Africa presenting with possible TB (all patients initiated 
on TB treatment). Fresh random and early morning urine (EMU) samples (~10-30 ml) collected in 
sterile containers. Following the manufacturer’s instructions, an Alere Determine TB Lateral flow 
assay performed on each sample, using both grade 1 and 2 cut-points. A single sputum Xpert 
MTB/RIF and/or liquid TB culture was a reference standard. Those designated probable TB 
patients were sputum Xpert MTB/RIF and/ TB culture negative, but started on TB treatment.  
Results 
Of 184 HIV- infected adults screened, only 123 patients commenced anti-TB treatment  and provided 
matched random and  EMU samples. 33% (41/123) and 67% (82/123) had definite TB and probable 
TB, respectively. Amongst definite TB, LF-LAM sensitivity, using the grade 2 cut-point, increased 
to 39% (95% CI: 26-54, 16/41) from 12% (95% CI: 5-24, 5/41) using EMU versus random, respectively 
(p=0.004). Similarly, amongst probable TB, urine LAM sensitivity increased to 24% (95% CI: 16-34, 
20/82) (p=0.01) from 10% (95% CI: 5-17, 8/82). Age, CD4 cell count, Xpert MTB/RIF/liquid TB 
culture positivity and prior initiation of anti-TB treatment within 7 days were not significant 
predictors of an increasing urine LAM grade between random and EMU specimens.  LF-LAM 
specificity was not determined. 
Conclusions 
EMU sampling can improve the sensitivity of LF-LAM testing for hospitalised TB/HIV co-infected 
patients. There is a need for further research is to assess if this additional diagnostic sensitivity can 
affect patient-important outcomes.  
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Introduction 
The HIV pandemic has fueled a resurgence of tuberculosis (TB), the leading cause of death 
in HIV-infected persons in sub-Saharan Africa (1). Rapid initiation of TB treatment may 
reduce mortality in these vulnerable patients, making early diagnosis an imperative (36, 56). 
However, there are several hurdles to diagnosis including lack of sputum production, 
sputum bacillary concentrations below the detection threshold of same day diagnostic tests, 
and atypical clinical presentation.  High frequency of extra-pulmonary (EPTB) and 
disseminated forms of TB with advancing immunosuppression is aggravated.  
 
Thus, there is a urgent need for new, accurate, and rapid non-sputum-based TB diagnostics 
that have high sensitivity in patients with HIV/TB co-infection with advanced 
immunosuppression (57). The Alere Determine®-TB LAM Ag lateral flow assay (Alere, 
USA; referred to as LF-LAM) that detects urine lipoarabinomannan, a M.tb cell wall-
associated glycolipid, is the most  promising, and only commercially available option (52). 
LAM is a point-of-care test that is simple to use, requires no instruments, provides a result 
in just 25 minutes and is low cost (<US $3.50 per test). Importantly, it is non-sputum based 
and is therefore useful for patients who cannot produce sputum (29). A LAM-guided 
treatment strategy has recently been shown to reduce mortality in hospitalized HIV-
infected inpatients with suspected TB (58). However, LF-LAM sensitivity remains sub-
optimal (40- 60% in HIV co-infected patients with a CD4 count < 100 cells/ml) (59). Thus, 
strategies to improve sensitivity are urgently required. 
 
Early morning urine (EMU) is accepted as a useful method for improving the concentrations 
of a number of antigens and analytes found in human urine (57, 60). The strategy has been 
shown to improve the yield of urine culture for TB diagnosis (61). Thus, we hypothesised 
that collecting early morning urine compared to a random spot urine specimen may be a 
simple and effective strategy to improve the sensitivity of LAM in hospitalised HIV-infected 
patients with possible TB.  
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STUDY POPULATION AND METHODS 
 
The study population comprised HIV-infected adults (>18 yrs.) prospectively recruited 
between June 2012 and February 2014 from four hospitals: New Somerset, Victoria, 
Mitchells Plain and Groote Schuur Hospital, in Cape Town, South Africa. HIV-infected 
patients were referred for screening by emergency room or hospital doctors, if they were 
HIV-infected, older than 18 years and suspected to have TB.  They were enrolled if they: 1. 
Provided informed consent, 2. Were able to provide both random and early morning urine 
sample, and 3. Initiated anti-TB treatment either based on clinical and radiological findings, 
or sputum-based smear or Xpert MTB/RIF positivity. The exclusion criteria was as follows: 
1. all rapid sputum-based TB diagnostics were negative and no treatment was initiated 
based on clinical and radiological findings, and 2. they were unable to provide matched 
random and early morning urine samples.  
All patients enrolled provided written informed consent and had basic clinical information 
collected, including demographics, past history of TB, presenting symptoms and vital signs. 
The University of Cape Town Human Research Ethics Committee (HREC REF 720/2013) 
approved the study 
 
Tuberculosis case definitions 
The reference standard for TB was single sputum sample positive liquid TB culture and/or 
Xpert MTB/RIF assay. Definite TB required a clinical presentation compatible with TB, 
initiation of anti-TB treatment by the attending clinician, with any sample M.tb culture or 
Xpert MTB/RIF positive. Probable TB required a clinical-radiological picture compatible 
with TB, and initiation of anti-TB treatment by the attending clinician, but M.tb culture 
and/or Xpert MTB/RIF negative. All non-TB patients from use in the analysis given the 
known limitations of single sputum-based TB diagnosis in HIV-infected patients with 
advanced immunosuppression.  
 
TB Diagnostic Sampling and Testing 
Consultant-led hospital-based clinicians, who were not associated with the study, 
determined the timing and extent of TB diagnostic work-up and the commencement of anti-
TB treatment. Routine hospital practice includes the collection, where possible, of two 
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sputum samples in patients able to expectorate. Sputum-based reference testing performed 
on admission and prior to treatment commencement, this was either on the same-day or 
prior to LF-LAM testing. The local reference laboratory processed all clinical specimens 
collected for TB diagnosis. Xpert MTB/RIF assay and/or culture, using MGIT 960 liquid 
culture system (BD Diagnostics, USA), was performed on sputum or non-sputum samples 
and Xpert MTB test was performed according to manufacturer’s instructions (62). 
  
Urine Sampling and LF-LAM Methodology 
All patients were required to give a random urine sample (30ml) collected in a 
sterile container at enrolment. EMU collected the following day, first void urine of 
the day between 05h00 am and 07h00 am. The LF-LAM was done on spot samples 
at the bedside and additionally on matched frozen-thawed spot and EMU 
specimens. Sputum-based reference testing was performed in parallel. All samples 
were tested using the Alere Determine®-TB LAM Ag lateral flow assay (Alere, 
USA). Briefly, 60l of urine pipetted onto the lateral flow strip-loading bay 
(pipettes provided with the strips). After 25-35 minutes, two independent readers 
blinded to the reference test results read the LF-LAM. This was done via the 
following procedure: test validity was confirmed by identifying the presence of a 
band in the positive control window; the intensity of the colour band (if any) in the 
patient window was read by comparison with the pre-January 2014 manufacturer-
provided visual reference scale card (graded 0–5 depending on band intensity). 
Using the manufacturer-recommended grade 2 cut-point, a band of visual intensity 
≥ grade 2 in the patient window was classified as a ‘positive’ test  while the 
complete absence of a band (grade 0) and faint band (grade 1) in the patient 
window was classified as a ‘negative’ test. The test reported as invalid if no control, 
either band identified in the patient window or if a broken / incomplete band seen 
in the patient window. Invalid tests repeated once, but thereafter LF-LAM was 
considered to have failed.  Discrepancies found between two readers in binary 
readout of positive or negative were resolved by the third reader. 
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Statistical Analysis 
Descriptive statistics for baseline demographic and clinical characteristics are used. 
Diagnostic accuracy measures included only sensitivity with the 95% confidence interval. 
2 testing used to compare sensitivity proportion between spot and EMU samples. 
Predictors of an increased LF-LAM grade between random and EMU performed, using 
multivariate linear regression. Data was analysed, using STATA software, version 11. 
Evaluation of the diagnostic test parameters was done with a Diagnostic or Screening Test 
Evaluation 1.0, using OpenEpi (Open Source Epidemiologic Statistics for Public Health, 
Version 3.03a. www.OpenEpi.com). The STARD criteria was utilised for all reporting and 
analysis (63). 
 
RESULTS 
184 patients were enrolled, but 61 patients were excluded as they had all sputum-based TB 
diagnostics negative and were not given treatment (n=52) or were unable to provide a urine 
sample at the time of enrolment (n=9) (Figure 1). The median age (IQR) was 36 (31-41) years 
and 58% of patients were female. The majority of patients had advanced 
immunosuppression with a median (IQR) CD4 of 88 (36-209) cells/ml. 
 
LF-LAM sensitivity in spot versus EMU 
Of 184 HIV- infected adults screened, only 123 patients commenced anti-TB treatment  and 
provided matched random and  EMU samples. 33% (41/123) of included patients had 
culture/Xpert MTB/RIF positive and classified as definite TB and 67% (82/123) had other 
diagnostic features suggestive of TB, including clinical findings, radiological evidence 
suggestive of TB (chest x-ray, ultrasound), and clinical symptoms and commenced on 
treatment. This are the patients classified as probable TB. Table 1 shows the sensitivity of 
LF-LAM in random versus EMU samples for definite- and probable-TB groups. Overall 
(definite- and probable-TB combined), the sensitivity (95% CI) of EMU improved from 10% 
(6-17) to 30% (22-38) with EMU (p= 0.0003 using the grade 2 cut- point.  Limiting the analysis 
to only patients with definite TB, LF-LAM sensitivity, using the grade 2 cut-point, increased 
from 12% (5-24) to 39% (26-54), in random versus EMU samples, respectively (p=0.004); 
amongst probable TB, LF-LAM sensitivity increased from 10% (5-17) to 24% (16-34) (p=0.01). 
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The data was stratified by CD4 counts of >200, <200, <100 and <50 cell/mm3 to determine whether, 
as in other studies, CD4 cell count plays a significant role in LF-LAM grade (figure 2). There were 
no differences noted between random and EMU specimen sensitivity for individual CD4 strata 
Predictors of increased LF-LAM positivity between spot and EMU 
None of Age, Xpert MTB/RIF /liquid TB culture positivity or prior initiation of anti-TB treatment 
within 7 days was significant predictors of an increasing LF-LAM grade between spot and EMU 
specimens (Table 3). 
 
 
Discussion 
The WHO has recently endorsed the use of LF-LAM testing for hosptialised HIV-infected patients 
with suspected TB (59) . In addition, our group recently published a multicentre RCT showing that 
a LAM-guided early TB treatment initiation strategy reduced all-cause mortality amongst this 
vulnerable patient group (58). However, test sensitivity remains sub-optimal, and simple strategies 
that could improve test sensitivity are necessary. This proof-of-principle study suggests that using 
EMU can increase the sensitivity of LF-LAM testing compared to random spot urine sampling. This 
could further improve the utility of LF-LAM for hospitalised HIV infected patients with advanced 
immunosuppression and possible TB.  
 
A number of strategies already been published or are being examined to improve the sensitivity of 
LAM. Efforts are being made to optimise the immune-detection methods used with the 
development of high avidity monoclonal LAM antibodies or aptamer technologies that could 
improve both sensitivity and specificity (52). Differing approaches for concentrating urine samples 
after collection to improve sensitivity have included heating, centrifugation and/or molecular 
weight exclusion filtration (52). None of these approaches is the ideal answer. Designing a new 
LAM assay will take many years of development, while these concentration methods all require 
laboratory infrastructure and human resources, unavailable in many places where testing is most 
in need. Therefore, a natural method for antigen concentration namely EMU sampling may be a 
good, ease-to –implement strategy. One other recent study showed no improvement in LF-LAM 
sensitivity from a two urine sample strategy; however, EMU sampling was performed up to seven 
days after the 1st spot urine was collected, and the timing of morning sampling is not stipulated  
(64). This delay in sampling may have dropped LAM concentration and offset the benefit of early 
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morning sampling. Further studies are now required to confirm our findings, consider any impact 
on specificity, and most importantly to assess the impact on patient-important outcomes.  
 
Our study did not find any factors that were associated with an increase in EMU LAM concentration, 
(as measured by the change in LF-LAM grade). Factors known to affect LAM concentration, such as 
CD4 cell count, age and culture/Xpert MTB/RIF status were not associated with an increased LF-
LAM grade (65). This seems biologically plausible given that these factors would likely be 
unchanged between spot and EMU sampling time-points. It is likely that more immediate 
physiological factors, such as blood pressure, hydration status and consequent glomerular filtration 
rates are more important determinants of increased EMU LAM concentration. Interestingly, we did 
not find that anti-TB treatment initiated either prior to both spot and EMU or between spot and 
EMU, testing was associated with increased EMU LAM. This is against previous observation and 
the “treat-to-test” hypothesis, which suggests that the concentration of bacillary antigens, such as 
LAM, may increase immediately following the initiation of anti-TB treatment due to death and 
metabolism of bacilli (55). Perhaps the effect of treatment on systemic antigenemia is not as large as 
hypothesized and other factors such as complexing of LAM to serum proteins have larger influence 
on urinary LAM concentrations.   
 
Our study had several limitations. Our study had limitations. The sample size was small and we 
did not collect sufficient co-variate physiological data to adequately understand which patients are 
likely to have an increase in urine LAM with EMU sampling. The study did not examine the effect 
of EMU on test specificity, and reduced specificity can negatively affect patient outcomes. However, 
the primary aim of this study was proof-of-principle to demonstrate that EMU could improve 
diagnostic sensitivity. We were concerned that specificity findings would be misleading given the 
misclassification bias associated with use of a single sputum TB culture/Xpert MTB/RIF for TB 
diagnosis in this HIV-infected population with advanced immunosuppression. 
 
The study highlights the diagnostic implications of the timing of sample collection with EMU testing 
significantly improving LF-LAM sensitivity in hospitalised TB/HIV co-infected patients. In this 
vulnerable patient group, EMU LF-LAM, in addition to spot testing on admission, and irrespective 
of empiric treatment initiation, may add value. Larger studies are now required to confirm our 
findings and importantly, to determine if the incremental sensitivity can translate to impact on 
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patient important outcomes or if the delay in time required between spot and EMU sampling 
negates the benefits of testing.  
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Table 1. Overall sensitivity of the urine LAM, using random versus EMU samples, 
and stratified by diagnostic category and preceding anti-TB treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sensitivity  
95% (CI) 
Manufacturer recommended LF-LAM 
positive cut point (grade 2) 
P-value 
Random Urine 
%, 95% CI, n/N 
Early Morn. Urine 
%, 95% CI, n/N 
Definite- TB only 12 
(5-24) 
(5/41) 
39 
(26-54) 
(16/41) 
0.004 
Probable TB only 9.6 
(5-17) 
8/82 
24 
(16-34) 
20/82 
0.01 
Definite and Probable 
TB combined 
10 
(6-17) 
(13/123) 
30 
(22-38) 
(36/123) 
0.0003 
No TB Rx prior 11 
(4-28) 
(3/27) 
31 
(17-50) 
(8/26) 
0.05 
TB Rx prior  
< 7 days 
10 
(2-40) 
(1/10) 
56 
(27-81) 
(5/9) 
0.04 
No TB Rx prior 15 
(8-27 ) 
(8/52 
25 
(15-38) 
(13/52) 
0.1 
TB Rx prior  
< 7 day 
0 
(0-11) 
(0/30) 
23 
(12-41) 
(7/30) 
0.003 
No TB Rx prior 14 
(8-23) 
(11/79) 
30 
(18-38) 
(21/78) 
0.03 
TB Rx prior  
< 7 days 
2 
(0-12) 
(1/42) 
30 
(18-45) 
(12/40) 
0.0006 
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Figure 2: Overall sensitivity of the urine LAM strip test for TB diagnostic, using random versus  
EMU samples, and stratified by diagnostic and CD4 count 
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Table 2. Multivariate predictors of increasing urine LF-LAM test grading between 
random and EMU specimens 
 
 
 
 
P-value 
Adjusted 
Odds Ratio 
Lower 95% CI                Upper 95% CI 
                                                                                         All (n=61) 
Age, years 0.32 0.967 0.906                         1.03 
CD4 cell count, cells/mm3 0.92 1.000 0.996                         1.005 
TB culture/Xpert positive 
(pos/neg) 
0.15 2.201 0.760                          6.379 
TB treatment < 7 days 0.41 1.59 0.53                           4.81 
